HSPA5 and thyroid cancer, nonmedullary, 2: In our study, the reduced expression observed for the HSPA5 gene in the malignant tumor samples group (PTC and FTC) (group 2) and in the PTC samples group (group 4), compared to the group of normal and benign samples (group 1) by PCR Array analysis, confirmed by RT-qPCR analysis, indicates this gene as a diagnostic marker in malignant tumors.